International Compliance Program: Core Risk Areas

Moffitt Cancer Center focuses on these risks in its new international compliance program (see story, p. 1)[1] and has mitigation strategies for all of them, said Chief Compliance Officer Donnetta Horseman. For example, with respect to biologicals, “International Compliance should review all new biosafety protocols as they are presented to the biosafety review board. A team member from international compliance should also attend biosafety committee meetings as needed to hear more about certain biologicals and their use within the protocol.” Contact her at donnetta.horseman@moffitt.org.

This document is only available to subscribers. Please log in or purchase access.
 


Would you like to read this entire article?

If you already subscribe to this publication, just log in. If not, let us send you an email with a link that will allow you to read the entire article for free. Just complete the following form.

* required field